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Abstract  
Background 
In 2014 the UK National Institute for Health and Care Excellence recommended reducing the 
threshold for offering statin therapy to patients from a 10 year modelled risk of 
cardiovascular disease (CVD) of 20% to 10%.  
Aim  
To describe the response of patients in UK primary care with a CVD risk between 10-20% to 
an invitation to attend a consultation to discuss statins. 
Design and Setting  
Review of electronic medical records at one GP practice in the East of England. 
Method 
We invited all patients who had attended an NHS Health Check at the practice, had a QRisk® 
score between 10-20% and were not prescribed statins to attend designated clinics in the 
practice to discuss starting statins. We reviewed the medical records to identify those who 
had attended the clinics and those who had chosen to start a statin. 
Results 
Of 410 patients invited, 100 (24.4%) patients attended the designated clinics and 45 (11%) 
chose to start a statin. Those who chose to start a statin were older and with a higher QRisk® 
than those did not. Among those who attended, individuals who started a statin had a higher 
QRisk® than those did not and were more likely to be current or ex-smokers. 
Conclusions 
The proportion choosing to start a statin was substantially lower than previously estimated. 
Large population based studies with long-term follow-up are needed to assess the impact on 
health and workload of this change in guidance. 
  
  
What is already known about this topic? 
In 2014 NICE recommended reducing the threshold for offering statin therapy to patients for 
primary prevention of cardiovascular disease from a 10 year modelled risk of CVD of 20% to 
10%.  At the time this generated widespread controversy but little is known about the impact 
of this guidance in real life. 
 
What does this article add?  
Our study is the first to report the effect of this change in guidance in practice.  One in four 
patients with a modelled risk of 10-20% took up the offer of a consultation to discuss statins, 
and one in ten started a statin.  This is considerably lower than estimated by NICE.  
 
 
 
  
INTRODUCTION 
In 2014 the UK National Institute for Health and Care Excellence  (NICE) updated its 
guidance on primary prevention of cardiovascular disease (CVD) and recommended reducing 
the threshold for offering statin therapy to patients from a 10 year modelled risk of CVD of 
20% to 10% (1,2).  This change in risk threshold generated widespread controversy (3).  It is 
estimated that the new guidance will make 4.5 million more people eligible for statins and 
according to NICE will save up to 4,000 lives and prevent 8,000 strokes and 14,000 non-fatal 
heart attacks over 3 years (2). However, there are concerns over the potential increased risks 
of harm and limited evidence of benefit to those at lower (10%) risk.   
These population benefits and concerns will only be seen if a sufficiently high 
proportion of people at lower cardiovascular risk wish to first consider taking a statin and 
then actually take it (4). However, there is increasing recognition that people are reluctant to 
start treatment. Expert opinion from NICE (5) suggested that up to 20% of the population 
between 10-20% risk would choose not to take statins following discussion with their 
healthcare professional, but there are limited data from this specific group. Whilst the 
accompanying costing report also did not anticipate these changes having a significant 
resource impact (5), there were concerns over the increased workload the change in 
guidelines would generate for GPs, particularly at a time when resources within the NHS are 
already under pressure.  
We aimed to describe the response to an invitation to patients with a CVD risk 
between 10-20% to attend a consultation to discuss statins in order to estimate the impact of 
the updated guidance in UK primary care.   
 
METHOD 
Setting 
This study was performed in a National Health Service Primary Care Practice in 
Cambridgeshire, UK serving a predominantly white population of 11,588 patients with a 
deprivation score of 6.5 (IMD) (6).  
 
Patients 
We searched the practice electronic records to identify all patients who had attended 
an NHS Health Check at the practice between 1
st
 April 2011 and 1
st
 December 2014 and who 
had a QRisk® score ≥ 10% and <20% recorded at the time of that health check.  Patients had 
initially been invited based on registration date with the practice and at the time of that health 
check had been given lifestyle advice by a practice nurse and then informed that only those 
with a QRisk® over 20% would be contacted and informed of their risk.  The patients in this 
study had, therefore, received lifestyle advice but no direct feedback about their risk or 
discussion about statins. We reviewed the records of those with a previous or current 
prescription for a statin to identify current users (those who had received a prescription for a 
statin between 1
st
 October 2014 and 1
st
 December 2014), prior users (those with one or more 
prescriptions for a statin in the records but none between 1
st
 October 2014 and 1
st
 December 
2014), and those with a documented intolerance to statins.   
      
Intervention 
Prior users of statins were contacted by the surgery and invited to book an 
appointment to discuss the new guidance and alternative statin preparations.  Current users 
and those with a documented intolerance to statins were not contacted.  All other patients 
were sent a letter informing them of the recent change in NICE guidance and that they were 
in the group which had previously not been offered statin medication but which may benefit.  
A patient information leaflet was enclosed providing more information on the new 
recommendations, how the risk of heart disease or stroke is calculated, what statins are and 
how they work, the benefits and harms of taking statins, and generic lifestyle advice 
(Appendix 1).  The information on the benefits of statins was taken from the National 
Prescribing Centre Statins Patient Decision aid which is freely available at 
http://www.webarchive.org.uk/wayback/archive/20140627120928/http://www.npc.nhs.uk/the
rapeutics/cardio/cd_lipids/resources/pda_Lipids.pdf and included the same iconographs as in 
that document. The information on the harms of statins was taken from the published 
literature (7).  
In the information leaflet patients were encouraged to take steps to improve their 
lifestyle where possible and were invited to make an appointment in designated clinics if they 
wanted to discuss starting a statin or any of the other information in the leaflet. Designated 
clinics were then held in the surgery by one of the practice GPs (JUS) for these patients.  
Letters were sent out in batches of 100 over an 8 week period to ensure appointments in the 
clinics were available. During clinic appointments patients were told their own QRisk® score 
based on their initial health check.  In addition, the effect of changes in lifestyle and increased 
age both since the previous health check and into the future was illustrated using the online 
QRisk® calculator available at www.qrisk.org.  Discussions around the benefits and risks of 
statins were based on the information already provided in the patient information leaflet.  
Those patients initially reluctant to take statins were offered the opportunity for further 
review in the future and were advised of the date on which they would be invited for a 
follow-up NHS Health Check (5 years after their initial Health Check).  
 
Data collection 
 At the time of the initial search of the practice electronic records, data were extracted 
for age on 1
st
 December 2014, gender, ethnicity, most recent smoking status, BMI, systolic 
blood pressure, total cholesterol:HDL ratio, recorded family history of ischaemic heart 
disease in a relative < 60 years,  history of diabetes, chronic kidney disease, atrial fibrillation, 
or rheumatoid arthritis, prescriptions for antihypertensive drugs (excluding those used for 
erectile dysfunction), and number of repeat tablet medications (excluding paracetamol, 
codeine, ibuprofen and drugs prescribed for erectile dysfunction).    
Contemporaneous entries were recorded in patient medical records at the time of 
review in each of the separate clinics held in the surgery as part of routine clinical practice. 
Four weeks after the last letters were sent out, we searched the practice electronic records to 
identify all those who had attended the designated clinics and those who had been started on a 
statin. We manually searched the medical records of those patients reviewed in the clinics to 
extract the recorded reason for declining, if applicable, and the records of those patients who 
did not attend the clinics but had been started on a statin.  
 
Analysis 
All analyses were performed using Stata version 12 and data values are expressed as 
mean (SD).  Fisher’s exact test and Student’s unpaired t-test were used to compare groups for 
categorical and continuous variables respectively. Logistic regression was used to compare 
characteristics of those attending the clinics and those subsequently starting a statin. To 
account for collinearity between the QRisk® score and the individual risk factors separate 
logistic regression was performed with all the risk factors included in the QRisk® score. 
Ethnicity was excluded as it was only available for 172 of the 413 patients and as the practice 
population is 94.4% white British (6) it was unlikely that any effect of ethnicity would be 
seen. Statistical significance was set at p<0.05. 
 
RESULTS 
1,646 patients had attended an NHS Health Check in the practice. The mean (SD) age 
was 58.1 (9.1) years and 54.6% were male.  1016 (61.7%) had a QRisk® <10%, 452 (27.5%) 
a score ≥10% and <20%, and 178 (10.8%) a score ≥20%. Of the 452 with a  QRisk® ≥10% 
and <20%, statins had been prescribed to 20 within the 2 months prior to December 2014, ten 
had a history of taking a statin in the past and four had recorded intolerance of statins.  Five 
patients had moved out of the area. Letters and information leaflets were sent to the 
remaining 413 patients. 
Those 413 patients had a mean (SD) age of 64.8 (6.1) years and 56.2% were male.  
The QRisk® scores were distributed throughout the range from 10-20% with the mean (SD) 
13.9 (2.6) (Figure 1).  
On medical record review two patients had died and one had been started on a statin 
following a stroke. Of the remaining 410, 100 (24.4%) patients had attended the designated 
clinics.  At those appointments, 7 patients had a QRisk® below 10% following changes in 
lifestyle and 42 (10.2% of all those invited and 42% of those who booked an appointment to 
discuss statins) chose to start a statin. Five patients chose to have a blood test for an up-to-
date lipid profile. None of those 5 subsequently chose to start a statin. Three other patients 
had started taking a statin having made appointments with other GPs in the practice 
specifically to discuss the letter that they had received.  Of the original 410 patients a total of 
45 (11.0%) chose to start a statin.      
The characteristics and distribution of QRisk® score of all 410 patients, those 
attending the surgery, and those choosing to start a statin are shown in Table 1 and Figure 1. 
There were no statistically significant differences between those who attended and those who 
did not.  Those who chose to start a statin were older and with a higher QRisk® than those 
who did not and, of those who attended, those who started a statin had a higher QRisk® than 
those who did not and were more likely to be current or ex-smokers than non-smokers. 
None of the risk factors included in the QRisk® score (age, bmi, gender, smoking 
status, anti-hypertensive medication, systolic BP, chol:hdl ratio, family history of IHD in a 
first degree relative <60 years, or deprivation) were associated with attendance at the surgery 
and neither were the QRisk® score, the number of current repeat medications or the time 
since the initial health check.  Among the initial 410 patients, age was the only risk factor 
associated with starting a statin, with older patients more likely to choose to start a statin (OR 
1.12 (95% CI: 1.01 to 1.24)), and those with a higher QRisk® also more likely to start a statin 
(OR 1.14 (1.01 to 1.28)).  Among the patients who attended the surgery, increasing age and 
QRisk® were also associated with starting a statin (OR 1.19 (1.03 to 1.36) and 1.34 (1.13 to 
1.60) respectively).  In this group, both ex-smokers and current smokers were also more 
likely to start a statin than non-smokers (OR 11.9 (1.05 to 127.7) and 2.93 (1.06 to 8.12) 
respectively). 
The most common documented reasons for not wishing to start a statin were either not 
wanting to take medication (n=23) or preferring to initially change lifestyle to reduce risk 
(n=12).  Other reasons included concern about side effects in general (n=5) and preferring to 
wait a few years and then reassess (n=5) (Table 2).      
 
DISCUSSION 
Summary 
To our knowledge this is the first study to report the uptake of statins amongst people 
with a 10-year CVD risk of between 10 and 20%.  It shows that in a group that had 
previously attended a Health Check, one in four took up the opportunity to discuss starting 
statins and one in ten chose to start a statin.  Those who attended the surgery represented a 
cross-section of the entire group invited whilst those who chose to start a statin tended to be 
older with higher CVD risk.   
 
Strengths and limitations 
The main strength of this study is that the study population is a well-defined cohort of 
patients who had all attended an NHS Health Check in the same practice.  As the same 
template had been used for data entry, the coding of risk factors was consistent and there was 
very little missing data. Holding designated clinics in the practice for capacity reasons also 
meant that patients all saw the same GP and received the same lifestyle advice and 
information on the benefits and risks of statin therapy.  Whilst every attempt was made to 
provide this information in a uniform and non-influential manner, it is, however, possible that 
the consultation style affected their choice and in routine practice GPs and nurses may differ 
in their approach to these discussions.  The response by patients to updated guidance as in 
this study may also differ from the response to contemporaneous discussion of their risk 
using only the updated NICE guidance. The initial letter also did not provide an individual 
risk estimate. It is, therefore, possible that some of the patients who attended the clinics did 
so just to find out their QRisk® score and that, if that had been included in the letter, the 
number attending the practice would have been smaller.  It is also possible that some patients 
chose to discuss statins with other GPs in the practice. We think this number is low, however, 
as only three patients started a statin outside the specific clinics and all GPs were advised to 
ask patients to book into the separate clinics if they wished to discuss the letter that they had 
received. Another limitation is that the practice is in an area of low deprivation with a 
predominantly white British population and low prevalence of cardiovascular disease risk 
factors.  This makes the findings potentially less generalizable to other UK populations and 
caution is needed when extrapolating to the wider NHS.  
 
Comparison with existing literature 
The distribution of CVD risk amongst those who had attended a health check in the 
practice was similar to that reported in other studies: 10.8% had a CVD risk ≥20% compared 
to two other studies which reported 10.5% (8,9); and 38.3% had a risk ≥10% compared to 
33.3% reported across 3 PCTs in London (8).  No direct comparison is available for the 
response rate to the letters of invitation (24%) but it was lower than the uptake of initial 
health checks in Cambridgeshire (37%) (10).  
The low rate of initiation of statins (11%) is consistent with other studies, albeit in 
different groups of patients. Reports from the NHS Health Check programme showed that 
even in people at high cardiovascular risk (≥ 20%) prescription of statins increased from 25% 
to only 45% (11); up to 40% of first-time statin users prefer to use diet control before 
initiating statin therapy (12); 5% of people on the streets of London would choose not to take 
a statin even if it gave them another five years of life (13); and people responding to a US 
based internet survey would pay an average of $1445 (£948; €1265) to avoid taking one pill a 
day for cardiovascular disease prevention. 
 
Implications for research and/or practice 
In 2013-2014, 1,382,864 people had an NHS Health Check in England (10).  Whilst 
caution is needed extrapolating the results of this observational study in one GP practice to 
the wider NHS, if the findings were applied to that population, offering statin treatment to all 
those with a risk between 10-20% would potentially result in an additional 380,287 people 
being offered statins and 95,535 additional nurse or doctor led consultations. This is less than 
the 25% increase in GP appointments included in the sensitivity analysis in the NICE 
costings report (5). However, at a time when general practice is under significant pressure, 
even this small increase may have resource implications. GP surgeries offering Health 
Checks need to be aware of this potential increase in workload.  
The proportion (42%) choosing to start a statin after discussion is also lower than the 
80% estimated in the costings report (5) and highlights both the reluctance of the majority of 
people at low risk to take statins and the difficulty of implementing population-based 
strategies with small benefits to individuals.  It also means that the long term benefits of these 
additional consultations will be smaller than expected.  Nevertheless, if 42% of patients chose 
to start a statin, in England 41,831 patients would have been prescribed statins in 2013-2014 
and using data from a Cochrane systematic review of statin therapy (14) this would have led 
to 36,811 additional patients taking statins long-term and the prevention of 267 deaths from 
all causes, 751 CVD events and 237 strokes and an estimated 371 new cases of diabetes over 
5 years.  
The effect of the reduction in risk threshold may also have additional effects beyond 
the prescription of statins.  The most common reasons for not starting a statin in this study 
were either not wanting to take medication or preferring to initially change their lifestyle.  
Having been faced with the option of a statin it is, therefore, possible that more people would 
be encouraged to make changes to their lifestyle, if only to avoid having to take statins in the 
future.  The true impact of this change in guidance will, therefore, only be clarified by large 
population based studies with long-term follow-up.  
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Table 1. Characteristics of patients 
Characteristic All (n=410) Attended (n=103) Started statin (n=45) 
Age (years) 64.7 (6.12) 65.5 (6.11) 66.6 (5.96)* 
Males 231 (56%) 55 (53%) 23 (51%) 
Smoking status    
   Non-smoker 229 (56%) 62 (61%) 22 (50%)** 
   Ex-smoker 142 (35%) 35 (34%) 18 (41%) 
   Current smoker 35 (9%) 5 (5%) 4 (9%) 
BMI (kg/m
2
) 27.3 (4.82) 26.7 (4.11) 26.6 (4.45) 
Deprivation    
   Highest tertile 370 (91%) 94 (92%) 38 (86%) 
   Middle tertile 37 (9%) 8 (8%) 6 (14%) 
   Lowest tertile 1 (0.2%) 0 (0%) 0 (0%) 
FH IHD < 60 years 105 (26%) 22 (21%) 8 (18%) 
QRisk 10-year CVD risk 13.9 (2.64) 13.7 (2.6) 14.7 (2.3)*/** 
Systolic blood pressure 132.7 (13.8) 131.2 (13.8) 133.1 (14.8) 
Cholesterol:HDL 4.06 (1.07) 3.97 (1.09) 3.97 (1.12) 
Antihypertensive medication 21 (5%) 4 (4%) 2 (4%) 
Diabetes 1 (0.2%) 0 (0%) 0 (0%) 
Chronic kidney disease 1 (0.2%) 0 (0%) 0 (0%) 
Atrial fibrillation 6 (1.5%) 1 (1%) 0 (0%) 
Rheumatoid arthritis 3 (0.7%) 1 (1%) 1 (2%) 
Regular medication    
    None 232 (57%) 55 (53%) 23 (51%) 
    1-3 medications 153 (37%) 43 (42%) 20 (44%) 
    >3 medications 25 (6%) 5 (5%) 2 (4%) 
Time since health check (months) 28.0 (10.3) 28.1 (9.82) 28.0 (10.6) 
 
Data presented as mean (SD) unless specified 
* p<0.05 compared to all others who had chosen not to start a statin 
**p>0.05 compared to those who had attended but chosen not to start a statin 
  
Table 2. Reasons for not choosing to start a statin 
  
Reason n 
Not keen on medication 23 
Prefer to initially change lifestyle 12 
Concern about side effects in general 5 
Prefer to wait a few years then reassess 5 
Undecided at present 3 
Concern about developing diabetes 2 
Concern about the impact on travel insurance 1 
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Figure 1. Distribution of Qrisk® scores amongst all patients sent a letter, those who attended clinics 
and those starting a statin 
PATIENT INFORMATION LEAFLET 
Your personal Statin Decision 
What are the new recommendations? 
For many years medications called statins have been prescribed for patients who have 
previously had a stroke or heart disease (angina, previous heart attack etc) and for people 
who have a risk of having a heart attack or stroke of 20% or greater over the next 10 years.  
Recently, however, the National Institute for Health and Care Excellence (NICE) has 
recommended that GPs offer statin medications to individuals whose estimated risk of 
having a heart attack or stroke in the next ten years is between 10% and 20%. 
 
How is risk of heart disease or stroke calculated? 
We currently calculate people's risk by using a tool called the 'QRisk'.  This calculates an 
individual’s risk using a combination of age, blood pressure, gender, ethnicity, smoking 
status, diabetes status, family history of heart disease, cholesterol, body mass index (which 
reflects a combination of your height and weight), and postcode.  The risk is presented as an 
estimated percentage risk of developing heart disease or stroke in the next ten years.  A risk 
of 10% means that if there were 100 people with the same age, blood pressure, gender etc 
as you, then our best estimate is that 10 of them will have a heart attack or a stroke in the 
next 10 years.  Although QRisk is the most sophisticated available tool, it is only able to give 
an estimated risk.  A high risk does not mean you are destined to have a heart attack or a 
stroke, and a low risk does not mean you are without risk. Lifestyle factors, such as diet and 
physical activity, which we know are important in preventing heart attacks and stroke, are 
also not directly included in QRisk, although they do have a beneficial effect on weight, and 
blood pressure which are included. 
 
What are statins? 
Statins are a group of drugs that help prevent heart attacks and strokes.  Examples include 
Simvastatin, Atorvastatin and Pravastatin.  They mainly work by lowering the cholesterol, a 
type of fat in the blood that leads to blockage of blood vessels, They may also reduce risk of 
heart attack and stroke in other ways, for example by reducing inflammation.  
 
 
 
What are the benefits of taking statins? 
There is good evidence to show that statins can reduce risk of stroke or heart disease by 
about a quarter (25%).  The benefit you will get depends on your individual risk and 
someone at higher risk is likely to benefit more than someone at lower risk.   
For example, for 100 people with a 10% risk, about 10 of them will have a heart attack or 
stroke over the next 10 years.  If all 100 take a statin for 10 years: 
- About 3 people will be ‘saved’ from having a heart attack or stroke (the yellow faces) 
- About 90 people will not have a heart attack or stroke – but would not have done even 
if they had not taken a statin (the green faces) 
- About 7 people will still have a heart attack or stroke even though they took a statin 
(the red faces) 
By comparison, for 100 people with a 20% risk, about 20 of them will have a heart attack or 
stroke over the next 10 years.  If all 100 take a statin for 10 years: 
- About 5 people will be ‘saved’ from having a heart attack or stroke (the yellow faces) 
- About 80 people will not have a heart attack or stroke – but would not have done even 
if they had not taken a statin (the green faces) 
- About 15 people will still have a heart attack or stroke even though they took a statin 
(the red faces)  
What are the harms of taking statins? 
Statins, like all medications, can cause side effects. Most people, however, tolerate them 
well and don’t experience any problems.  The most common side effects include: 
- Muscle aches and pains (about 10 out of 100 people but it is difficult to know exactly 
as muscle aches and pains are very common in people not taking statins) 
- Inflammation of the liver that almost always reverses on stopping the medication 
(approximately 1 in 1000 people taking a statin for 4 years) 
- A small increased risk of developing diabetes (about 1 in 200 people taking a statin 
for 4 years) 
Very rarely these side effects can be serious.  Some patients also report effects on memory 
and energy levels, although as with muscle aches and pains it is difficult to estimate how 
common this is as these are also very common in people not taking statins. There is no 
evidence that statins cause cancer or dementia or increase your risk of dying from other 
diseases.  
What should I do now? 
Whether you chose to take a statin or not, we would encourage you to take steps to improve 
your lifestyle where possible. In particular, the recommendations are: 
- To stop smoking 
- Eat a healthy diet  
o Rich in wholegrain starches and low in sugar and saturated and unsaturated fat 
with saturated and mono-unsaturated fats replaced with olive oil or rapeseed 
oil 
o With at least 5 portions of fruit and vegetables per day 
o With at least 2 portions of fish per week, including a portion of oily fish 
o With at least 4 to 5 portions of unsalted nuts, seeds or beans, peas or lentils 
per week 
- Keep physically active, aiming to do at least 150 minutes of moderate activity that 
makes you out of breath or 75 minutes of vigorous activity per week and muscle-
strengthening activities on 2 or more days a week  
- Work towards achieving and maintaining a healthy weight 
- Limit alcohol intake to 3-4 units per day for men and 2-3 units a day for women (a unit 
is approximately half a pint of ordinary lager, bitter or cider, half a glass of wine or one 
measure of spirits)  
Further details are available on the NHS Choices website under the ‘Live Well’ tab 
(www.nhs.uk/livewell) and in the Healthy Living leaflet available in the practice. As well as 
reducing your risk of heart attack and stroke, improving your lifestyle will also reduce your 
risk of developing other long-term conditions, including cancer.  
If you would like to discuss starting a statin or any of the other information in this leaflet then 
Dr Usher-Smith is holding separate clinics in the surgery so please contact the practice and 
ask to make an appointment in one of ‘Dr Usher-Smith’s health check clinics’. 
